Dominecia Maxwell
Family · Sunnyvale, TXNPI 1811650245
Payments from drug & device makers
Across 141 payments — averaging $19.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$529
- AbbVie$278
- Astellas Pharma US Inc$210
- Lilly USA, LLC$195
- Otsuka America Pharmaceutical, Inc.$148
- Pfizer$138
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,68196%
- Education$1004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 29 | $529 |
| AbbVie | 15 | $278 |
| Astellas Pharma US Inc | 8 | $210 |
| Lilly USA, LLC | 12 | $195 |
| Otsuka America Pharmaceutical, Inc. | 6 | $148 |
| Pfizer | 7 | $138 |
| Boehringer Ingelheim | 6 | $130 |
| AstraZeneca | 7 | $104 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $100 |
| Corcept Therapeutics | 2 | $92 |
| Sanofi-aventis U.S. LLC | 5 | $83 |
| Dexcom, Inc. | 4 | $82 |
| Merck | 3 | $70 |
| Bayer | 3 | $63 |
| Organon | 1 | $60 |
| Boston Scientific | 1 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Dynavax Technologies Corporation | 3 | $53 |
| GSK | 3 | $52 |
| Exact Sciences | 3 | $51 |
| Antares Pharma, Inc. | 3 | $47 |
| Amgen | 2 | $37 |
| Xeris Pharmaceuticals, Inc. | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| Roche Diagnostics Corporation | 1 | $21 |
| Ironwood Pharmaceuticals, Inc | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
How this compares
$2,781 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 76 | $91,310 |
| OzempicSemaglutide | 58 | $87,660 |
| FarxigaDapagliflozin Propanediol | 51 | $66,304 |
| MounjaroTirzepatide | 21 | $45,213 |
| EliquisApixaban | 30 | $44,006 |
| JanuviaSitagliptin Phosphate | 39 | $40,458 |
| RybelsusSemaglutide | 17 | $36,092 |
| LinzessLinaclotide | 35 | $34,525 |
| TrulicityDulaglutide | 14 | $32,733 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $30,794 |
| UbrelvyUbrogepant | 11 | $11,629 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $6,035 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $5,686 |
| Praluent PenAlirocumab | 12 | $5,653 |
| Gabapentin | 138 | $3,294 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $529 | $123,75275 claims |
| Boehringer IngelheimJardiance | $130 | $91,31076 claims |
| Lilly USA, LLCMounjaro, Trulicity | $195 | $77,94635 claims |
| AstraZenecaFarxiga | $104 | $66,30451 claims |
| AbbVieLinzess, Ubrelvy | $278 | $46,15446 claims |
| PfizerEliquis | $138 | $44,00630 claims |
| MerckJanuvia | $70 | $40,45839 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $52 | $36,82940 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.
Other family in Sunnyvale
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.